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associated with how much they perceived that their ADHD 
affected their lives. In a multiple regression model, the 
variance of MARS total (R2 = 0.21) and “intentional non-
adherence” (R2 = 0.24) was explained by the “BMQ-neces-
sity–concern differential” and “BMQ-experienced side 
effects”. The variance of “unintentional non-adherence” 
(R2 = 0.12) was explained by the “BMQ-necessity–con-
cern differential” and “B-IPQ-consequences of ADHD”. In 
conclusion, adolescents on long-term medication reported 
good adherence, mainly influenced by more beliefs in the 
necessity versus concerns of the medications, less expe-
rienced side effects and more perceived consequences 
of ADHD. BMQ could be useful to identify risks of low 
adherence, which should be counteracted by partially gen-
der-specific interventions.
Keywords ADHD · Adolescents · Medication beliefs · 
Perception · Treatment adherence
Introduction
Attention deficit hyperactivity disorder (ADHD) is a neu-
ropsychiatric disorder found in about 7% of children [1] 
and in approximately 3.4% of adults [2]. ADHD is treated 
primarily by medications such as methylphenidate (MPH), 
amphetamine and atomoxetine (ATX), in combination with 
psychoeducational measures and support [3, 4]. Stimulants 
like MPH lead to a more general increase of dopamine in 
the brain, while ATX increases norepinephrine selectively 
and dopamine indirectly in the frontal cortex [5]. Adoles-
cence is a vulnerable period and the expression of ADHD 
during this period may have destructive effects on the 
entire life course, resulting in fewer friends, school difficul-
ties and dismissals, arrests, unwanted pregnancy, sexually 
Abstract Adherence to attention deficit hyperactivity 
disorder (ADHD) treatment is important because, when 
untreated, it may have serious consequences with lifelong 
effects. In the case of adolescents on long-term medicine 
prescription, more knowledge is needed regarding adher-
ence and factors influencing adherence, which was the pur-
pose of this study. Adolescents (n = 101) on ADHD medi-
cation ≥6 months were administrated questionnaires at a 
monitoring appointment: Medication Adherence Report 
Scale (MARS), beliefs about medicines (BMQ) and the 
Brief Illness Perception Questionnaire (B-IPQ). Adher-
ence was high, the mean value was 88% of the maximum 
MARS score, and correlated positively with the “BMQ-
necessity-concerns differential” but negatively with “BMQ-
concerns” and “BMQ-side effects”. Adolescents with more 
belief in the necessity of the medication, less concerns and 
less experience of side effects tended to be more adherent 
to medication prescription (“intentional non-adherence”), 
while “unintentional non-adherence” (forgetfulness) was 
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transmitted diseases and abuse of drugs or alcohol [6–8]. 
However, medical treatment for individuals with ADHD is 
reported to reduce the risk of substance abuse [9], comor-
bid psychiatric disorders [10] and criminality [11]. In gen-
eral, adherence is important in achieving treatment effects 
[12]. For instance, high adherence to ADHD medication in 
school settings has been shown to yield higher academic 
grades among young people with ADHD [13].
Adolescents in the process of detachment from parental 
supervision might especially be expected to be less adher-
ent [14], at least compared with younger children under 
parental supervision [15–17]. Available evidence shows 
adherence failure in about 50% of children and adolescents 
[18]. On the other hand, adherence has been found to range 
between 20 and 81% in groups of adolescents [13, 18]. 
Hodgkin et al. [19] noted 49% mean adherence in ADHD 
adolescents, whereas Marcus and Durkin [13] found adher-
ence to stimulant treatment in only one young person out of 
five as defined by ≥70 in the medication possession ratio 
(MPR = the number of dispensed medication doses divided 
by the number of days in a unit of time multiplied by 100).
Medication treatment behaviour may be described in 
terms of the time on medication or discontinuation, often 
called persistence [20], or adherence, which captures the 
extent to which a patient’s actions correspond to the treat-
ment agreement recommendations of the health-care pro-
viders [12]. Varying definitions and methodological het-
erogeneity are responsible for the wide range of outcomes 
on adherence to ADHD medications. Adherence investiga-
tors have used database information on refill intervals or 
pill counts, patient/care-giver surveys and semi-structured 
interviews, but there are few studies based on serum con-
centration measurements [21–24].
Adherence is a multidimensional phenomenon com-
prising factors related to the patient, condition, therapy, 
health-care system, and socioeconomic circumstances [12]. 
Regarding ADHD, factors linked to the patient, therapy, 
and the condition have been found to affect adherence to 
pharmacological treatment, including general factors such 
as culture and body mass index [23], age and gender [24]. 
One previous study on a group of children and teenagers 
with ADHD revealed higher adherence among females 
[24]. Regarding pharmacological factors, non-adherence 
behaviour has been reported to increase in children and 
adolescents with a longer period of medication [22, 25]. 
Side effects were associated with negative feelings towards 
the ADHD medication and less adherence in an earlier 
qualitative study [14]. Furthermore, parents of 6 to 18-year-
old children with ADHD pinpointed minimal medication 
effects and side effects as among the most common reasons 
for discontinuing medication [26]. As many as 29% of chil-
dren and adolescents report non-serious adverse events of 
methylphenidate, according to a recent Cochrane review 
[27], and therefore it appears that side effects are important 
to take into consideration in adherence studies. The evi-
dence is limited and conflicting regarding the influence of 
the type of ADHD medication on adherence. Barner et al. 
[24] found 67% less adherence to immediate-release stimu-
lant treatment compared with non-stimulant treatment in 
children aged 3–18 years. Wehmeier et al. [25] found simi-
lar rates of adverse events and discontinuation of treatment 
with stimulants versus non-stimulants. Although MPH has 
been reported to have a higher response rate or efficacy 
than ATX [28], it is not known how important this factor 
is in comparison to other factors influencing adherence in 
adolescents on ADHD medication, especially with regard 
to the findings of Barner et al. [24]. Hence, the exact rela-
tionship of adherence with the benefits and risks of medica-
tions seems unclear in young people with ADHD, although 
this topic has been addressed previously in studies based 
on parents [29, 30]. However, Ferrin et al. [31] argued that 
adolescents’ beliefs about the medication have a higher 
weighting than the real benefits and risks, and this was 
further highlighted by Charach et al. [32] who found that 
young persons’ beliefs and attitudes have increasing impact 
on medication use as the decision-making shifts from the 
parent to the young person concerned. The belief that medi-
cation is effective combined with minimal experience of 
adverse effects has been shown to increase willingness to 
use ADHD medication for adolescents [33, 34].
The Beliefs about Medicines Questionnaire (BMQ-
Specific) [35, 36] may be used to study the relative impact 
of beliefs about the benefits versus risks of medication 
on adherence and is a measure of the necessity-concerns 
framework (NCF) [37, 38], which is an expansion of Lev-
enthal’s Common-Sense Model (CSM) [39]. The CSM aids 
the understanding of adaption and management of health 
and illness threats [40] and constitutes five domains of ill-
ness representation: Identity, timeline, cause, consequences 
and control [41]. Another related and useful questionnaire 
in adherence investigations is the Brief Illness Perception 
Questionnaire (B-IPQ), which is also based on the CSM 
[41] and explores perceptions about the illness. To date, 
there is only limited information available on perception 
about ADHD among adolescents, and none regarding pos-
sible influences on their adherence to medication. Adoles-
cents have endorsed diverse experiences, such as perceiving 
ADHD as a chronic physical illness [32], but also positive 
attributes of having ADHD, or equality with peers [42].
The self-report Medication Adherence Report Scale 
(MARS) [46] is advantageous in clinical settings because it 
is short, with only five items. To our knowledge, MARS has 
not been used to study adherence in ADHD. This is unfor-
tunate, because MARS may contribute to existing knowl-
edge by specifically exploring intentional and unintentional 
non-adherence [43, 44]. Intentional non-adherence is based 
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on an active decision not to take the medication as pre-
scribed, whereas unintentional non-adherence is due to fail-
ure to carry out the intention to take the medication because 
the medicines are too expensive or due to forgetfulness 
[43]. To our knowledge, none of the instruments mentioned 
above have been used for investigating adherence to ADHD 
medications in adolescents, although they are used in other 
disorders [37, 45].
The aim was to increase knowledge regarding adherence 
in adolescents on long-term ADHD medication prescription 
and in particular the influence of beliefs about the medi-
cation and perception of ADHD, in addition to age, time 
on medication and gender; all of which, we hypothesized 
would have an impact on adherence.
Methods
Procedure
Participants were recruited from two child and adoles-
cent psychiatric clinics (CAP) in Sweden between March 
2014 and June 2015. All adolescents (13–17 years) on a 
long-term prescription of ADHD medication for at least 
6 months were consecutively enrolled in the study. Exclu-
sion criteria were autism spectrum disorder, mental retar-
dation (IQ < 70), neurological disorders and language bar-
riers (e.g. inability to answer questionnaires in Swedish). 
Information about the study was sent with the letter setting 
up an appointment for ordinary monitoring of prescribed 
ADHD medication. Written informed consent was obtained 
both from the adolescent and parent/guardian at the time 
of the visit. Then, in the presence of the study nurse, the 
questionnaire was handed out and filled in. In order to 
get independent results, it was explained that the answers 
would never reach the doctor or staff responsible for treat-
ment. In addition to socio-demographic questions, the 
questionnaire included the following self-reports: MARS 
[46], BMQ-Specific [35, 36] and the B-IPQ [41]. The study 
was approved by the Regional Ethical Review Board in 
Linköping (D-nr 2013/402-31).
Participants
In total, 148 or 92.5% of the 160 patients invited to partici-
pate were included and gave written informed consent, of 
whom 101 or 68.2% (mean age of 15.6 ± 1.4 years), filled 
in the questionnaires; 66 (66.3%) boys and 35 (34.7%) girls 
(see flow-chart in supplementary online material). The girls 
tended to be older (p = 0.058) and had a longer pharma-
cological treatment (p = 0.098). The ADHD diagnosis was 
determined in accordance with DSM-IV criteria by an expe-
rienced CAP specialist after a thorough neuropsychological 
investigation encompassing careful clinical examination, 
questionnaires and, in most cases, 92% (93/101), also sup-
ported by a computer-based assessment of the ADHD core 
symptoms, the QbTest (Qbtech. Quantitative behaviour 
technology. https://www.qbtech.com/. Accessed 31 March 
2016). All participants had ADHD combined type and had 
a mean (SD) time on medication of 50.7 (29.3) months 
(Table 1). Eighty-one of the patients (80.2%) were taking 
long-acting MPH formulations and 9 (8.9%) ATX only 
and 11 ATX (10.9%) in combination with MPH (Table 1). 
In Sweden, MPH is recommended as first-line treatment, 
whereas lisdexamphetamine was only recently registered, 
at the time of the study, and immediate release ampheta-
mines could only be prescribed with a special licence and 
are therefore hardly used. No significant differences regard-
ing gender, age at the start of medication and time on medi-
cation were detected in an attrition analysis in which the 47 
non-respondents were compared with the 101 participants.
Questionnaires
Medication Adherence Report Scale
The MARS questionnaire is a self-report scale for assess-
ment of adherence to prescribed medication and consists 
of five statements, one concerning the subscale of unin-
tentional non-adherence (item 1; “I forgot to take them”) 
and four concerning the subscale of intentional non-adher-
ence behaviours (item 2; altering the dosage, item 3; stop-
ping taking medication, item 4; missing a dose, and item 
5; taking less than instructed) [46]. The items are rated on 
a 5-point scale, ranging from 1 = very often to 5 = never. 
Higher scores indicate higher levels of adherent behaviour. 
Previous studies using dichotomization of MARS conflict 
as regards a potential correct cut-off point for defining 
adherence [47–51]. We defined high adherence as ≥92% of 
total MARS scores (23 of 25). This cut-off point was pre-
viously used by another MARS researcher, Mårdby et al. 
[49], and seemed an appropriate choice in our population in 
which relative high adherence was expected. In the present 
study, Cronbach’s alpha for MARS was 0.52.
A separate question “Do you stop taking your ADHD 
medication during week-ends and school vacations?” was 
included in the questionnaire (i.e. in addition to MARS) to 
evaluate how many that sometimes paused their medication 
as allowed by the doctor.
Beliefs about Medicines Questionnaire‑Specific
BMQ-Specific has three subscales and eleven questions that 
capture beliefs about the prescribed medication. The items 
are rated on a 5-point scale ranging from 1 = “strongly 
disagree” to 5 = “strongly agree” (overall range, 5–25) [35, 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Eur Child Adolesc Psychiatry 
1 3
36]. A total score is not calculated as the subscales capture 
somewhat different dimensions going in opposite directions. 
Therefore, only the scores of the subscales and the differ-
ential are used in statistical analysis. The specific–necessity 
subscale is based on five questions and investigates beliefs 
about the necessity of prescribed medication for control-
ling ADHD symptoms and maintaining health (e.g. “my 
life would be impossible without my medicines”). The spe-
cific–concerns subscale consists of five questions regard-
ing concerns about the negative consequences of taking the 
medication (e.g. “I sometimes worry about the long-term 
effect of my ADHD medication”). A necessity–concerns 
differential score was calculated by subtracting the scores 
of the specific–concerns scale from those of the specific–
necessity scale (range −20 to 20). Therefore, a positive 
differential score indicates stronger beliefs in the necessity 
to medicate than concerns about consequences and on the 
contrary, a negative score indicates stronger concerns. The 
third subscale, is the one item that involves side effects, 
“I get unpleasant side effects from my ADHD medicines” 
[35] and was analysed separately due to reports about side 
effects of ADHD medication and their known role in non-
adherence behaviour [46]. In the present study, Cronbach’s 
alpha was 0.80 for the specific–necessity scale and 0.75 for 
the specific–concerns scale.
The Brief Illness Perception Questionnaire
The B-IPQ is a 9-item self-report scale that covers respond-
ents’ perceptions regarding ADHD. A total score is not cal-
culated since the questions aim to capture different percep-
tions, therefore only the scores of the individual items are 
used in statistical analysis. The first eight items are rated 
between 0 and 10. Five items assess cognitive dimen-
sions (timeline (chronic vs acute), identity, consequences, 
and personal and treatment control of ADHD). Two items 
measure emotional dimensions (concern about ADHD and 
emotionally affected by ADHD). One item assesses ADHD 
comprehensibility. A higher score reflects a stronger per-
ception of the respective item regarding ADHD [41]. 
Item 9 is an open question, which was not included in this 
analysis.
Statistical analysis
The Statistical Package for the Social Sciences (SPSS) 21.0 
was used. Descriptive statistics, frequencies, means, and 
standard deviations were calculated. Mann–Whitney’s U 
test was used to compare mean scores between high/low 
adherence, gender and medication groups. The Chi-squared 
test was used to compare frequencies between two dichoto-
mized group variables (high/low adherence vs gender). 
There were too few adolescents using either ATX alone or 
in combination with MPH, to permit any powerful statisti-
cal analysis. Therefore, all users of ATX (with or without 
MPH) were united and called the “ATX group” to give 
some information about possible differences in adherence 
behaviour between ATX and MPH-only consumers. Pear-
son’s correlation coefficient (95% confidence interval) was 
used to explore the associations, in the total sample and 
separately for gender, between scores in the total MARS 
and its subscales “intentional and unintentional non-adher-
ence” with age, time on medication, “BMQ-specific sub-
scales” and the “BMQ differential score”, as well as the 8 
items in B-IPQ. A total score is not used or calculated for 
the BMQ-specific and B-IPQ scales and is therefore not 
included in the analyses. Three different stepwise multi-
ple regression models were created in which the scores of 
(a) the total MARS, (b) intentional and (c) unintentional 
non-adherence subscales were used as dependent variables 
[52, 53]. Those variables which had a p value less than 
0.10 in the prior correlation analyses (Person’s correlation, 
Table 2) with the total MARS, intentional and unintentional 
non adherence subscales were included as independent 
variables. The independent variables included in the model 
were in (a) and (b); “the BMQ-specific-necessity”, “the 
BMQ-specific-concerns”, “the BMQ-necessity-concerns 
differential”, ”the BMQ-unpleasant side-effects” and in 
model (b) also time on medication, and finally in model (c); 




Adherence was measured by MARS, and detailed statis-
tical information is found in Table 1. The mean score for 
the whole group was 22.0, which is 88% of the maximum 
score. High adherence behaviour in accordance with our 
definition (92–100% of maximal MARS scores) was found 
in 46.5% (n = 47) of cases. The total MARS scores showed 
no difference regarding the time on medication, type of 
medication treatment, age or gender. Adolescents tak-
ing ATX with (p = 0.041). or without MPH (p = 0.044), 
compared with those solely on MPH, reported significantly 
more unintentional non-adherence (Table 1). In total, 50 
adolescents (49.5%) endorsed not taking medication during 
weekends and holidays; 15 always, 11 often, 10 sometimes 
and 14 rarely.
Beliefs about ADHD medications
Beliefs about medication, captured by the BMQ, are 
shown in Table 1. Girls endorsed stronger beliefs than boys 
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regarding the necessity of ADHD medication (p = 0.033). 
The “BMQ necessity–concern differential” scores were 
positive in the majority of cases or 83.2% (n = 84), nega-
tive in 11.9% (n = 12) and zero in 4.9% (n = 5). Partici-
pants in the ATX group had significantly more concerns 
about their treatment (p = 0.004) and received lower scores 
on the “BMQ necessity-concerns differential” (p = 0. 004), 
than those solely on MPH. BMQ ratings were not influ-
enced by age or the time on medication (Table 2).
Adherence and beliefs about ADHD medications
Correlations between MARS and BMQ ratings are shown 
in Table 2. The scores for the total MARS, intentional and 
unintentional non-adherence subscales showed statisti-
cally significant negative correlations with the scores of 
the “BMQ, specific–concerns” subscale (p < 0.001–0.015) 
and positive correlations with the necessity–concerns dif-
ferential score (p < 0.001–0.006). The ratings for the total 
MARS as well as the intentional subscale showed statisti-
cally significant negative correlations with the score on the 
BMQ side effects item (p = 0.004 and 0.003, respectively). 
Findings from the gender specific analyses are shown in 
Table 3. In girls, the scores for the total MARS, intentional 
and unintentional non-adherence subscales showed sta-
tistically significant positive correlations with the “BMQ, 
specific–necessity subscale” (p = 0.002–0.009), and the 
“BMQ necessity-concern differential” (p < 0.001–0.013). 
Table 2  Correlations of 
adherence measures by MARS 
and its subscales with beliefs 
about medication by BMQ-
Specific and perception about 
ADHD by B-IPQ among 
adolescents (n = 101) on long-
term ADHD medication
r Pearson correlation
* p < 0.05
** p < 0.01
a Medication Adherent Report Scale
b Beliefs about Medication Questionnaire-Specific
c The Brief Illness Perception Questionnaire
Total MARSa Intentionala Unintentionala Age Time on medication
r r r r r
Age −0.155 −0.134 −0.131
Time on medication 0.110 0.171 −0.092 0.278*
BMQ-Specific-necessityb 0.207* 0.186 0.157 −0.048 −0.038
BMQ-Specific-concernb −0.388** −0.371** −0.241* 0.171 0.030
BMQ-Differential scoreb 0.406** 0.379** 0.274** −0.146 −0.048
BMQ-side-effectsb −0.281** −0.288** −0.127 0.073 0.055
B-IPQ Consequencec 0.100 0.020 0.245* 0.188 −0.043
B-IPQ Timelinec 0.114 0.072 0.162 −0.063 −0.053
B-IPQ Personal controlc 0.119 0.130 0.033 0.047 −0.035
B-IPQ Treatment Controlc 0.107 0.078 0.124 −0.129 −0.162
B-IPQ identityc 0.039 0.022 0.060 −0.033 0.004
B-IPQ concernc 0.009 0.003 0.019 0.047 −0.015
B-IPQ comprehensibilityc 0.090 0.066 0.102 −0.025 0.072
B-IPQ emotional responsec 0.004 −0.044 0.118 −0.030 0.007
Table 3  Correlations of adherence measures by MARS and its subscales with beliefs about medication measures according to BMQ-Specific in 
adolescents (n = 101) on long-term ADHD medication shown separately for genders
r Pearson correlation









r p r p r p r p r p r p
BMQ-Specific–necessity 0.043 0.730 0.079 0.527 −0.075 0.552 0.504 0.002 0.434 0.009 0.480 0.003
BMQ-Specific–concerns −0.424 <0.001 −0.359 0.003 −0.322 0.008 −0.339 0.047 −0.361 0.033 −0.165 0.342
BMQ-Differential score 0.304 0.013 0.291 0.018 0.144 0.248 0.542 <0.001 0.511 0.002 0.418 0.013
BMQ-side-effects −0.131 0.295 −0.141 0.259 −0.023 0.864 −0.430 0.010 −0.447 0.007 −0.237 0.170
Eur Child Adolesc Psychiatry 
1 3
Total MARS and the intentional non-adherence subscale 
showed negative correlations with the BMQ side effects 
item (p = 0.010 and p = 0.007, respectively). For boys, the 
scores for the total MARS, intentional and unintentional 
non-adherence subscales showed statistically significant 
negative correlations with the “BMQ, specific–concerns” 
subscale (p < 0.001–0.008). In addition, the total MARS 
scores and intentional non-adherence showed a statistically 
significant positive correlation with the “BMQ necessity-
concern differential” (p = 0.013 and p = 0.018). The group 
with high as compared with low adherence scored signifi-
cantly higher on “BMQ necessity” (p = 0.002), lower on 
“BMQ concerns” (p < 0.001) and demonstrated a signifi-
cantly higher “BMQ necessity–concerns differential” score 
(p < 0.001) regarding the ADHD medication (Fig. 1). 
Perception of ADHD
Group differences regarding perception of ADHD between 
gender and medication groups were analysed with the 
B-IPQ (Table 1). Boys perceived that they could manage 
their ADHD (B-IPQ Personal control) better than girls 
(p = 0.005), whereas girls were more emotionally affected 
by their ADHD disorder (B-IPQ Concern, p = 0. 009, 
B-IPQ Emotional response, p = 0.026). The adolescents in 
the MPH group believed more strongly in the medication´s 
“controlling effect” of the ADHD symptoms (B-IPQ Treat-
ment Control, p = 0.038) than those in the ATX group.
Adherence and perception of ADHD
The total MARS scores for the whole group were gener-
ally not significantly correlated with the B-IPQ scores, age 
or time on medication (Table 2). However, the adolescents 
who felt that ADHD affected their life less (B-IPQ Conse-
quence, r = 0.25, p = 0.014) had higher ratings of unin-
tentional non-adherence. In girls the scores for the total 
MARS scale (r = 0.37, p = 0.027) and the intentional non-
adherence subscale (r = 0.40, p = 0.018) were positively 
correlated to the B-IPQ question regarding the belief that 
ADHD duration would be long-standing (B-IPQ Timeline). 
In boys, only the “unintentional non-adherence subscale” 
correlated with the B-IPQ question “How well do you feel 
you understand your ADHD?” (B-IPQ Comprehensibility, 
r = 0.27, p = 0.031). The gender analysis is not shown in 
Table 2.
Predictive factors for adherence to ADHD medication
In a stepwise multiple regression model (Table 4), two 
independent variables explained the variance of MARS 
total scores (R2 = 0.21), namely the necessity–concern 
Fig. 1  Comparison of medica-
tion beliefs among adolescents 
(n = 101) on prescribed ADHD 
medication divided into low 
versus high adherence groups
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differential and the BMQ side effects item. For intentional 
non-adherence (R2 = 0.24) time on medication also con-
tributed significantly. For unintentional non-adherence 
(R2 = 0.12) the necessity–concern differential and the 
B-IPQ Consequence item contributed significantly. A one-
unit increase in the necessity–concern differential increased 
the total MARS score by 0.14 and the intentional non-
adherence score by 0.11. A one-unit increase in the “expe-
rienced side effects” score decreased the MARS total score 
by 0.42 and the intentional non-adherence score by 0.38. A 
one-unit increase in time on medication increased the inten-
tional non-adherence score by 0.01. A one-unit increase in 
the necessity–concern differential increased the uninten-
tional non-adherence scores by 0.03. A one-unit increase 
in the B-IPQ consequence increased the unintentional non-
adherence score by 0.07.
Discussion
In a sample of adolescents on long-term ADHD medica-
tion, the mean adherence was high or 88% of maximum 
MARS score, and significantly associated with less expe-
rience of side effects and a positive differential of beliefs 
in the necessity versus concerns of medication. These find-
ings demonstrate that adolescents on long-term medication 
seem to be able to follow medication prescription despite 
increasing independence [14]. Age and length of the time 
on medication were not correlated to MARS total score. 
Gau et al. [54] found the opposite concerning age. How-
ever, they did also find that time on medication had no 
effect on adherence [54]. Adherence in this study is above 
average compared to the documented 9.8–71% adherence 
rates found in earlier studies of combined groups of chil-
dren and adolescents below 18 years of age, which used 
similar cut-off points for the definition of adherence or 
≥80% cut-off for MPR [15, 24, 55]. For instance, Marcus 
et al. [13] found 18% high adherence (defined as ≥70% for 
MPR) in a middle school group, whereas Hodgkin et al. 
[19] noted 49% mean adherence in adolescents in the same 
age-span as our population.
There are several methodological discrepancies that 
may explain the differences in the reported adherence rates, 
besides potential variations in follow-up routines and socio-
demographic factors. The longitudinal nature of previous 
studies compared with our cross-sectional method may have 
influenced the results because reliance on memory in cross-
sectional studies generates more inaccurate results. We did 
not replicate the repeatedly reported reduction of adherence 
with longer time on medication [15, 22, 25], probably due to 
the cross-sectional design, which may result in participant 
populations with different medication durations. Bypass-
ing the most critical period for drug adherence in the first 
6 months characterized by adverse events and early drop-
outs, probably also influenced the adherence rate and may 
underlie the absence of the otherwise anticipated associa-
tions between adherence and other factors such as time on 
medication [15, 56, 57]. Moreover, it could be questioned 
comparing with populations that also include younger chil-
dren, as their parents mostly ensure the continuity of the 
medication intake [22]. Finally, different assessment tools 
may lead to different adherence prevalence, although no 
method is recognized as optimal [12, 44] and most of the 
methods may overestimate compliance [58]. In the popula-
tion with ADHD, the self-report method has been shown to 
generate higher prevalence rates than found in more direct 
approach such as by measurement of saliva concentrations 
of MPH [21]. Furthermore, MARS captures forgetfulness, 
dosage alterations, missing doses, and taking less than the 
dose instructed as a measure of adherence, which are only 
indirectly comparable with information on refill inter-
vals or pill counts. Bearing the methodological differences 
described above in mind, our results should be interpreted 
with caution especially regarding generalizability.
Although, to our knowledge, this is the first time that 
MARS has been used to investigate adherence in ado-
lescents with ADHD, it has been used in studies of other 
chronic somatic disorders in the same age group [51]. The 
Table 4  The variables 
significantly explaining the 
variance of (a) MARS total, 
(b) the intentional and (c) the 
unintentional subscales in 
three corresponding multiple 
linear regression models in 
adolescents (n = 101) on long-
term ADHD medication
B regression equation, SE B standard error for B
a Beliefs about Medication Questionnaire-Specific
b The Brief Illness Perception Questionnaire
Variables Total MARS Intentional non-adherence Unintentional non-
adherence
B SE B p B SE B P B SE B p
BMQ-differential scorea 0.140 0.034 <0.001 0.110 0.028 <0.001 0.033 0.012 0.009
BMQ-side-effectsa −0.424 0.173 0.016 −0.377 0.142 0.009 – – –
Time on medication – – – 0.013 0.006 0.027 – – –
B-IPQ consequenceb – – – – – – 0.070 0.030 0.023
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adolescents with ADHD exhibited similar or even higher 
adherence (88%, measured as the percentage of the group’s 
mean/maximum MARS scores) than both adolescents 
(81%) [51] and adults (85%) [59] on asthma medication. 
This could be linked to the ADHD group’s proportionally 
stronger differential of belief in the necessity of the medi-
cation to control ADHD symptoms, relative to the concerns 
about negative consequences (larger positive differential).
The scores of the total MARS and its two subscales 
associated positively with the necessity-concern differential 
irrespective of whether investigated dichotomously (high/
low adherence), by correlation or with multiple regression 
analysis. Around 21% of the MARS total´s variance was 
explained by the “necessity-concern differential” together 
with “experienced side effects”. These two latter fac-
tors, in addition to time on medication explained 24% of 
the variance on the “intentional non-adherence” subscale. 
Finally, around 12% of the variance on the “unintentional 
non-adherence” subscale was explained by the “necessity-
concern differential”, together with the B-IPQ item “conse-
quences of the ADHD”. Taken together, the differential of 
beliefs in the necessity versus concerns about the medica-
tions, “experienced side effects”, time on medication and 
“perceived consequences of the ADHD” all influenced 
adherence to medication. These results not only provide 
evidence for the notion that teenagers weigh up beliefs 
about benefits versus risks of the medication as considering 
pros and cons of adherence [31, 32], but they also take into 
account the consequences of ADHD.
Furthermore, adherence was significantly inversely 
associated with the BMQ subscales scores of concerns 
about medication and “endorsed side effects”, according 
to both correlation and dichotomous analyses in line with 
previous data [14, 26]. The “concerns” subscale did not, 
however, survive the stepwise multiple regression analy-
ses, suggesting that it has a less important role amongst 
other non-adherence risk factors. The finding of an asso-
ciation between adherence and experienced side effects is 
reasonable in the light of the high frequency of reported 
non-serious adverse events secondary to stimulant treat-
ment [27], the high discontinuation rate due to adverse 
effects [56], and the reported relationship between experi-
ences of adverse effects and willingness to use medication 
[33]. Overall, these data suggest that the BMQ is a useful 
questionnaire for identification of risk factors of low adher-
ence behaviour when monitoring adolescents on long-term 
ADHD medication. The “BMQ- necessity-concerns dif-
ferential” seems to be a robust indicator of adherence; and 
shows that beliefs about the medication influence adher-
ence in adolescents on long-term ADHD medication. 
Hence, the present results emphasize the importance of 
clinicians being on the alert regarding beliefs about ADHD 
medication and the execution of efficient monitoring of 
side effects to enable subsequent appropriate actions to 
minimize them, such as a titration or switch of medication 
in order to achieve optimal symptoms control and hope-
fully good adherence [60, 61].
This is the first time, to our knowledge, that uninten-
tional and intentional non-adherence behaviour has been 
explored for ADHD medication in adolescents. The MARS 
total and the unintentional and intentional subscales mainly 
showed the same association patterns with beliefs about 
medication since they all correlated with “concerns about 
medication” and the necessity—concerns differential. The 
MARS subscale “intentional non-adherence” was associ-
ated with perceived short ADHD duration and experience 
of side effects in girls, often coinciding with a brief time on 
medication, which in turn was also related to “intentional 
non-adherence”. Hence, “intentional non-adherence” could 
be reduced by good monitoring of side effects and infor-
mation about ADHD and medication from the beginning. 
Regarding respondents’ perceptions about ADHD (accord-
ing to B-IPQ), the “unintentional non-adherence” subscale 
was significantly associated with the perception that ADHD 
only marginally affected their life. In other words forgetful-
ness could decrease when functional disturbances owing to 
ADHD become more impeding and the gains from medica-
tion more obvious. Such a notion complies with evidence 
of improved school functioning and quality of life with 
MPH [62], also recognized by adolescents as improved 
schoolwork and better peer relationships [34]. Furthermore, 
the unintentional non-adherence correlated inversely with 
“understanding of the nature of ADHD disorder” (in boys), 
pointing to the importance of psycho-education regarding 
medication and general knowledge about ADHD in adoles-
cents [33].
To our knowledge, this is the first study of gender dif-
ferences on adherence to ADHD medication in a sample 
limited to teenagers. No difference regarding adherence 
according to total MARS scores was detected between the 
genders, in agreement with a larger epidemiological adher-
ence investigation on several chronic disorders also based 
on MARS [63]. Nevertheless, some differences emerged 
in separate gender analyses. MARS and its two subscales 
associated negatively with “concerns about the medica-
tion” in boys, i.e. boys with more concerns tended to be 
less adherent. In girls, the necessity-concern differential 
and beliefs in the necessity of medication were associated 
with higher adherence. The finding of stronger belief in 
the necessity endorsed by the girls, as compared to boys, 
is concordant with results from adults with asthma [59] 
while, on the other hand, the association of concerns with 
adherence only in boys contradicts results from adults with 
asthma [64]. This suggests different mechanisms for these 
associations of beliefs with adherence in these chronic 
disorders.
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To summarize, adherence seems to have more associa-
tions with beliefs about the medication in adolescent girls 
than boys and suggests a need for partly gender-adjusted 
low-adherence prophylaxis. Adolescent girls may need 
more accurate dose titration and monitoring to eliminate 
side effects and information about ADHD progression, 
whereas the boys need more information about ADHD and 
medication to alleviate medication concerns. These find-
ings of gender differences in adherence behaviour in young 
people with ADHD need further research to clarify the 
exact underpinnings.
Adherence in general was not influenced by whether 
the medication consisted of ATX (with or without MPH) 
or only MPH in line with Wehmeier et al.’s [25] findings, 
but disagreeing with Barner et al. [24]. Yet, the ATX users 
independent of whether ATX was the sole treatment or used 
in combination with MPH, showed significantly more unin-
tentional non-adherence and to a lesser extent perceived 
that their ADHD was controlled by their treatment, than 
the MPH group. This may relate to the ATX users’s signifi-
cantly stronger concerns than beliefs in the necessity for 
medication, and also to their perception of less improve-
ment due to medication, in parallel with results on adults 
with asthma [65]. In addition, these results may mirror less 
successful treatment, since ATX is often a second-line med-
ication at the participating and other clinics [66], which in 
turn may have lower response rate/efficacy compared with 
MPH [28, 67]. It could be argued that since MPH and ATX 
pharmacological actions differ, it is unwise to group the 
ones taking both MPH and ATX together with only ATX 
users. However, the clinical experience is that patients tak-
ing combination therapy of MPH and ATX often claim 
that they experience less of “on–off” problems after add-
ing ATX. This suggests that the effect of ATX medication is 
pronounced also in this combination therapy. Although the 
adolescents on ATX were too few to permit any conclusive 
statements regarding differences in adherence behaviour 
between ATX and MPH users, the results seem worth fol-
lowing up with larger replication studies and suggest that 
ATX users, in particular, may benefit from more support, 
such as reminder packaging to improve adherence [68, 69].
The present study has some further limitations that 
should be considered. The decision not to investigate ado-
lescents at the start of medication limits information about 
initial adherence problems and dropouts. On the other hand, 
the population was more homogeneous. Consequently, the 
results can only be interpreted for adolescents on long-
standing stable medication. Using MARS as an indirect 
measure of adherence and not using a direct method (i.e. 
patient observation or pharmacological analysis) could 
have inflated results. In order to minimize a self-report bias 
due to the tendency to give a good impression the questions 
are worded in a “normalizing” non-adherent behaviour 
manner [43]. The MARS Cronbach’s alpha was a bit low 
[70] which along with the fact that the questionnaire only 
relies on one type of validation, i.e. item inter-correlations 
[71], constitute two relevant methodological limitations for 
conclusive interpretation of the adherence results. The fact 
that one-third of the patients were allowed to take “drug 
holidays” (i.e. only taking medication on school days) 
may have interfered with responses to the MARS item “Do 
you stop taking the medication for some time”, intended 
to capture non-adherence behaviour. This is suggested by 
a separate analysis of the 51 individuals who never took 
any prescribed drug holidays (and could not have misinter-
preted that question) where the proportion of high adher-
ents was considerably higher, or 67% as compared to the 
46.5% found in the whole group. Future studies are needed 
for better clarification of how prescribed drug holidays 
influence adherence measurements and for identifying the 
most optimal way to handle this dilemma. Furthermore, 
several factors that might contribute to unintentional non-
adherence such as comorbidity and socio-economic status, 
were not taken into account thereby limiting the general-
izability of findings. There may be a risk of alpha errors 
because of the number of performed analyses but no adjust-
ments were made for mass significance, because of the risk 
of over-adjusting the significance level due to high correla-
tions between most variables in the domains. Therefore, the 
results need to be interpreted with caution.
The socio-demographic attrition analyses showed no 
differences between participants and non-respondents that 
suggests minimal effects of attrition on the results. The 
rather high attrition after giving consent is most reasona-
bly explained by a tendency for teenagers and their parents 
to show cooperativeness when face-to-face with the care-
givers, which failed to survive throughout when filling in 
the questionnaire, especially for those bringing it home, 
in addition to the fact that many parents of children with 
ADHD themselves have problems with organization and 
fulfilling chores. However, it seems likely that the adoles-
cents who chose not to participate or return the question-
naires were less adherent and therefore underestimation of 
low-adherence behaviour and compromised elucidation of 
the underlying factors in our data are possible. On the other 
hand, 69% participation, of all those invited, is acceptable 
and was possibly due to the well-controlled care including 
good cooperation with parents and with the research team.
The main strengths of the study are the well-charac-
terized population due to the possibility of identifying all 
suitable patients undergoing medication at the participating 
clinics and the foregoing solid diagnostic work including 
neuropsychological investigation on which the diagnoses 
were based.
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Conclusions
Adherence was high overall in a well-controlled adolescent 
population with ADHD undergoing long-term pharmaco-
logical treatment and strongly associated with a positive 
differential of belief in necessity versus concerns of medi-
cation and less experienced side effects. Generally, gender 
differences regarding adherence to ADHD medication were 
not found. However, adherence in boys was more influ-
enced by concerns about medication and, in girls by beliefs 
in the necessity of medication and experience of side 
effects. The results underscore the usefulness of the BMQ 
questionnaire in identifying beliefs of relevance for adher-
ence, in particular in girls, while information about the 
perception of ADHD from the B-IPQ seems to have lim-
ited value. The results emphasize the importance of careful 
follow-up routines, including psycho-pedagogical informa-
tion, partly with a gender-specific focus.
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